For the Inventor, By the Inventor

Enter assignee name

Eligo Bioscience

USPTO Granted Patents = 38

EPO Patents = 3

Trademarks = 4

Forward Citations = 30

Loading Chart...

Loading Chart...

17 inventors (with patents filed for the assignee):

Antoine Decrulle (24 out of 24 patents)

Jesus Fernandez Rodriguez (23 out of 23 patents)

Xavier Duportet (22 out of 23 patents)

4. Aymeric Leveau (10 out of 10 patents)

5. Inès Canadas Blasco (10 out of 10 patents)

6. Aurélie Mathieu (10 out of 10 patents)

7. David Bikard (6 out of 20 patents)

8. Cristina Del Carmen Gil-Cruz (5 out of 5 patents)

9. Christian Ivan Pérez-Shibayama (5 out of 5 patents)

10. Burkhard Ludewig (5 out of 5 patents)

11. Andreas Brodel (4 out of 4 patents)

12. Thibault Carlier (4 out of 4 patents)

13. Igor Stzepourginski (3 out of 3 patents)

14. Lun Cui (2 out of 2 patents)

15. Antonina Krawczyk (2 out of 2 patents)

38 patents: Sort by Forward Citations

1. 12460216 - Phage-derived particles for in situ delivery of DNA payload into C. acnes population (2025-11-04),

2. 12454696 - recombinant phages encoding a human protein (2025-10-28),

3. 12414962 - Method for treatingbacteria-associated diseases (2025-09-16),

4. 12214070 - Cosmetic use of engineered postbiotics comprising bacteriocins and/or endolysins (2025-02-04),

5. 12214022 - Sequence-specific antimicrobials by blocking DNA repair (2025-02-04),

6. 12098372 - Microbiome modulation of a host by delivery of DNA payloads with minimized spread (2024-09-24),

7. 11970716 - Transcriptional control in prokaryotic cells using DNA-binding repressors (2024-04-30),

8. 11970701 - Phage-derived particles for in situ delivery of DNA payload intopopulation (2024-04-30),

9. 11952595 - Production of lytic phages (2024-04-09),

10. 11952594 - Pharmaceutical compositions comprising bacterial delivery vehicles and uses thereof (2024-04-09),

11. 11946056 - Optimized vector for delivery in microbial populations (2024-04-02),

12. 11939598 - Production bacterial cells and use thereof in production methods (2024-03-26),

13. 11905516 - Optimized vector for delivery in microbial populations (2024-02-20),

14. 11840695 - Recombinantphages comprising transgenes (2023-12-12),

15. 11839645 - Therapeutic use of engineered postbiotics comprising bacteriocins and/or endolysins (2023-12-12),

Eligo Bioscience is a biotechnology company that specializes in developing drugs based on CRISPR technology. They focus on using CRISPR-engineered bacteriophages to target and eliminate specific bacteria, providing potential alternatives to antibiotics. With their proprietary platform, Eligo Bioscience aims to revolutionize the treatment of serious bacterial infections and the prevention of bacterial resistance.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

38 Patents

#137 in Paris

#585 in France

#17,288 in the World

Eligo Bioscience

Forward Citations = 30

17 inventors:

Antoine Decrulle (24 out of 24 patents)

Jesus Fernandez Rodriguez (23 out of 23 patents)

Xavier Duportet (22 out of 23 patents)

4. Aymeric Leveau (10 out of 10 patents)

5. Inès Canadas Blasco (10 out of 10 patents)

Please report any incorrect information to support@idiyas.com

Loading…